Big Pharma Companies Acquire Two SoCal Biotech Startups

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Big Pharma Companies Acquire Two SoCal Biotech Startups
Photo by Sam Moqadam on Unsplash

Two Southern California biotech startups got swallowed up this week as big pharma benefitted from the record-breaking year of investment in the industry.


Pharmaceutical giant Eli Lilly plucked up a Pasadena startup Protomer Technologies for $1 billion. The company is working on "smart insulin" to treat diabetes.

Another SoCal startup, El Segundo-based Integrity Bio, was acquired by New York drug development company Curia, formerly known as AMRI. Terms of both deals weren't disclosed.

Biotech has been on a tear. Protomer, which last year received an undisclosed funding amount, is one of over a thousand companies who benefited from a banner year in biotech. According to Pitchbook, the industry saw a 60% year-over-year increase in venture capital deal activity in 2020 the largest year-over-year increase ever seen.

Those deals are coming to fruition now, as Protomer and Camarillo-based Integrity Bio, a formulation pharmaceutical upstart, are shedding the need for funding as they get acquired by pharmaceutical companies.

"If Big Pharma wants to start buying assets, more venture capital is going to start pouring into biotech because they know that Big Pharma will be interested in acquiring it down the road," said Bill Bolding, a senior analyst at Provident Healthcare Partners.

Eli Lilly's acquisition of Protomer will give it an even stronger hold on diabetes treatment. Eli Lily's most recent diabetes drug, tirzepatide, outperformed one of its market rivals, and the company is pursuing FDA approval. But glucose-sensing insulin is the next frontier of diabetes treatments, as it has the ability to take into account peoples' unique blood sugar levels.

"With insulin, it's a very complicated drug to use," said Ruth Gimeno, Eli Lilly's vice president of diabetes research. "It's a very efficacious drug, but current insulins are not as safe as we would like them to be. So glucose sensing insulin would just be a complete game changer here."

Curia, a company that formulates and manufactures drugs for other companies, will use Integrity Bio to establish a West Coast presence in the U.S. and get access to the former upstart's slew of clients ranging from startups to Fortune 500 companies. The acquisition is expected to close in the third quarter of 2021.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

Genies Wants To Help Creators Build ‘Avatar Ecosystems’

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

Genies Wants To Help Creators Build ‘Avatar Ecosystems’

When avatar startup Genies raised $150 million in April, the company released an unusual message to the public: “Farewell.”

The Marina del Rey-based unicorn, which makes cartoon-like avatars for celebrities and aims to “build an avatar for every single person on Earth,” didn’t go under. Rather, Genies announced it would stay quiet for a while to focus on building avatar-creation products.

Genies representatives told dot.LA that the firm is now seeking more creators to try its creation tools for 3D avatars, digital fashion items and virtual experiences. On Thursday, the startup launched a three-week program called DIY Collective, which will mentor and financially support up-and-coming creatives.

Read moreShow less

Here's What To Expect At LA Tech Week

Christian Hetrick

Christian Hetrick is dot.LA's Entertainment Tech Reporter. He was formerly a business reporter for the Philadelphia Inquirer and reported on New Jersey politics for the Observer and the Press of Atlantic City.

Here's What To Expect At LA Tech Week

LA Tech Week—a weeklong showcase of the region’s growing startup ecosystem—is coming this August.

The seven-day series of events, from Aug. 15 through Aug. 21, is a chance for the Los Angeles startup community to network, share insights and pitch themselves to investors. It comes a year after hundreds of people gathered for a similar event that allowed the L.A. tech community—often in the shadow of Silicon Valley—to flex its muscles.

From fireside chats with prominent founders to a panel on aerospace, here are some highlights from the roughly 30 events happening during LA Tech Week, including one hosted by dot.LA.

Read moreShow less

TikTok Creators Want To Unionize, But Experts Warn It Could Be 'Very Challenging'

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College and previously covered technology and entertainment for TheWrap and reported on the SoCal startup scene for the Los Angeles Business Journal. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

​TikTok logo and union laborers
Image courtesy of Andria Moore

Earlier this month, Business Insider reported that a group of around 75 TikTok creators formed a private Discord server to discuss the potential of forming a union. Led by Forrest Valkai, a science TikToker with 1.4 million followers, the group’s main gripe included their lack of stability.

Read moreShow less
https://twitter.com/samsonamore
samsonamore@dot.la
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending